Last updated: 2026-09-16 09:45:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Praxis Precision Medicines, Inc. (PRAX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $315.05, with a market capitalisation of $9.23B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $40.12 to $392.70. This page covers its latest market performance, valuation, price trends and company information.
$9.23B | |
$314.70 | |
$914.26 | |
$11.85 | |
$312.90 | |
1.11K | |
435.33K | |
-- | |
$392.70 | |
$40.12 | |
-- | |
-- |
Praxis Precision Medicines, Inc. (PRAX) is trading at $315.05 in pre-market trading as of 2026-09-16 08:41:00, up 0.69% ($2.15) from the previous close of $312.90
Pre-market trading shows how investors are pricing PRAX before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Praxis Precision Medicines, Inc. (PRAX) moved from $351.81 to $315.05, representing a decline of 10.45% ($36.76).
The stock traded between $311.98 and $360.61 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 255.21 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 78.0%
PRAX is currently trading at $315.05, placing it 78.0% of the way from its 52-week low of $40.12 to its 52-week high of $392.70. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 10998 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Praxis Precision Medicines, Inc. (PRAX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.